PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

ClinicalTrials.gov Identifier: NCT02957409

Novartis Reference Number: CLCZ696BCA03

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.

Condition 
Heart Failure
Phase 
Not Given
Overall status 
Active, not recruiting
Enrollment count 
1009 participants
Start date 
May 20, 2016
Completion date 
Oct 12, 2020
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Drug
sacubitril/valsartan
This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.

Eligibility Criteria

Inclusion Criteria:

Receiving sacubitril/valsartan as per the Canadian product label and treatment initiation within the last 3 months
Able to communicate with investigator

Exclusion Criteria:

Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days
Presence of any condition that in the opinion of the investigator, prohibits patient from participating in the trial

Study Locations

Canada
Novartis Investigative Site
-
Calgary, T2N 4Z6
Alberta
Canada
Novartis Investigative Site
-
Calgary,
Alberta
Canada
Novartis Investigative Site
-
Edmonton, T6G 2C8
Alberta
Canada
Novartis Investigative Site
-
Maple Ridge, V2X 2P8
British Columbia
Canada
Novartis Investigative Site
-
North Vancouver, V7M 2H4
British Columbia
Canada
Novartis Investigative Site
-
Winnipeg, R2H 2A6
Manitoba
Canada
Novartis Investigative Site
-
Moncton, E1G 1A7
New Brunswick
Canada
Novartis Investigative Site
-
Halifax, B3H 3A7
Nova Scotia
Canada
Novartis Investigative Site
-
Brampton, L6W 2X7
Ontario
Canada
Novartis Investigative Site
-
Burlington, L7M 4Y1
Ontario
Canada
Novartis Investigative Site
-
Cambridge, N1R 6V6
Ontario
Canada
Novartis Investigative Site
-
Newmarket, L3Y 2P6
Ontario
Canada
Novartis Investigative Site
-
Oakville, L6K 3W7
Ontario
Canada
Novartis Investigative Site
-
Sarnia, N7T 4X3
Ontario
Canada
Novartis Investigative Site
-
Scarborough, M1P 2V5
Ontario
Canada
Novartis Investigative Site
-
Sudbury, P3E 5M9
Ontario
Canada
Novartis Investigative Site
-
Toronto, M5G 2N2
Ontario
Canada
Novartis Investigative Site
-
Waterloo, N2T 0C1
Ontario
Canada
Novartis Investigative Site
-
Weston, M9N 1W4
Ontario
Canada
Novartis Investigative Site
-
Chicoutimi, G7H 5H6
Quebec
Canada
Novartis Investigative Site
-
Greenfield Park, J4V 2G8
Quebec
Canada
Novartis Investigative Site
-
Joliette, J6E 6J2
Quebec
Canada
Novartis Investigative Site
-
Laval, H7M 3L9
Quebec
Canada
Novartis Investigative Site
-
Levis, G6V 4Z5
Quebec
Canada
Novartis Investigative Site
-
Montreal, H1T 1C8
Quebec
Canada
Novartis Investigative Site
-
Montreal, H3G 1A4
Quebec
Canada
Novartis Investigative Site
-
Sainte Foy, G1V 4G5
Quebec
Canada
Novartis Investigative Site
-
Sherbrooke, J1H 5N4
Quebec
Canada
Novartis Investigative Site
-
St-George, G5Y 4T8
Quebec
Canada
Novartis Investigative Site
-
St-Jean-sur-Richelieu, J3A 1J2
Quebec
Canada
Novartis Investigative Site
-
Trois-Rivieres, G8Z 3R9
Quebec
Canada
Novartis Investigative Site
-
Quebec, G1R 2J6
-
Canada

Have a question?

Call 1-999-669-6682 or email [email protected]